SAN FRANCISCO — Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.
The 2013 California Biomedical Industry Report — by PwC, the California Healthcare Institute and BayBio — looked at California's biotech industry and how it faired in 2012.
